SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

The next Alzheimer’s treatment could come from an unexpected place. In new research released this week, scientists have found ...

Able to cross the blood-brain barrier, Xenon gas seemed to perk the mice right up, which began to become particularly active ...

Jan. 15, 2025 — Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a ...

Researchers report hopeful progress in efforts to find treatments for Alzheimer’s disease. They report a recent clinical ...

AD is a progressive, relentless disease caused ... of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale. Over three years of treatment across the Clarity ...

Two new PET radiotracers have outperformed the only currently Food and Drug Administration (FDA) approved radiotracer for detecting tau tangles in the brain, a hallmark of Alzheimer’s disease. In a ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE ...

Modeling simulations predict that transitioning to once every four weeks maintenance dosing after 18 months of once every two weeks treatment will maintain clinical and biomarker benefits of therapy.